Enhancement of CTL response induced by a viral peptide using cationized BSA, a Th1-stimulating adjuvant.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Enhancement of CTL response induced by a viral peptide using cationized BSA, a Th1-stimulating adjuvant.

Viral Immunol. 1994;7(4):179-88. Unique Identifier : AIDSLINE MED/96100712
Vasilakos JP; Michael JG; Department of Molecular Genetics, Biochemistry, and Microbiology,; University of Cincinnati, Ohio 45267-0524, USA.

Abstract: We have recently shown that it is possible to activate cytotoxic T cells (CTL) in vivo with HSV-1 glycoprotein B H-2Kb-restricted peptide (gB peptide) independent of CD4+ T cell help. Here we report that the gB peptide-specific CTL response is significantly enhanced when mice are immunized with a mixture of gB peptide and cationized BSA (cBSA). The latter molecule is a positively charged form of the native BSA molecule that stimulates CD4+ T cells to produce cytokines characteristic of Th1 cells. The cBSA-enhanced CTL response required the presence of CD4+ T cells, but it did not require stimulation in vitro by antigen or exogenous cytokines. gB peptide/cBSA-activated LN cells transcribed IL-2 and IFN-gamma, but only IL-2 was essential for CTL development. Our data demonstrate that while activation of CTL may occur in the absence of CD4+ cells, cytokines produced by CD4+ Th1 cells provide stimulatory signals during CTL maturation. Thus, cotreatment with a substance that activates Th1 CD4+ cells may be useful for achieving maximal CTL responsiveness.

Keywords: Adjuvants, Immunologic/*PHARMACOLOGY Animal Cations Cell Differentiation/IMMUNOLOGY Cytotoxicity, Immunologic/*DRUG EFFECTS Female Interferon Type II/PHYSIOLOGY Interleukin-2/BIOSYNTHESIS/PHYSIOLOGY Mice Mice, Inbred C57BL Serum Albumin, Bovine/CHEMISTRY/IMMUNOLOGY/*PHARMACOLOGY Simplexvirus/*IMMUNOLOGY T-Lymphocytes, Cytotoxic/DRUG EFFECTS/*IMMUNOLOGY Th1 Cells/*CHEMISTRY/METABOLISM Viral Envelope Proteins/IMMUNOLOGY/*PHARMACOLOGY JOURNAL ARTICLE
960228
M9621083

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .